The HeartWare HVAD Was Withdrawn After Higher Stroke and Death Rates. Here Is What the LVAD Evidence Trail Shows.

The Scene

In June 2021, Medtronic issued a voluntary field safety corrective action for the HeartWare HVAD, advising clinicians to stop new implants and informing the approximately 4,000 patients worldwide currently living with the device that a controller software issue had been identified that could cause the pump to fail to restart after a programmed stop. For patients who were pacemaker-dependent or who had no residual cardiac function, an HVAD restart failure could be fatal within minutes.

The FDA’s response was swift: the HeartWare HVAD was recalled from the U.S. market in June 2021, and Medtronic subsequently announced that it would permanently discontinue the HVAD program. Patients already implanted with the device were managed with enhanced monitoring protocols, more frequent controller battery checks, and, in some cases, transition to the HeartMate III through a device exchange operation.

The HVAD recall is not the end of the story. It is a moment in a longer arc: the history of left ventricular assist devices from the first pneumatic displacement pump in the 1960s to the fully magnetically levitated, near-silent centrifugal devices of the 2020s. That arc is a story about the gap between engineering possibility and biological tolerance, between solving one problem and creating another, and about what happens to real patients in the years between when a device is first approved and when its long-term failure modes become apparent.

The retired teacher in Evanston who received her HVAD in 2018 and learned in June 2021 that the device she had been living with for three years was being recalled is not a data point in a regulatory action. She is a person who had reconstructed a life around a machine that was now at the center of a safety crisis, and who needed to understand clearly: what was the actual risk, what was the plan, and was she going to be okay.

What It Is (and Was)

The HeartWare HVAD (HeartWare Ventricular Assist Device) was a centrifugal-flow LVAD manufactured by HeartWare International (subsequently acquired by Medtronic in 2016). The HVAD differed from the HeartMate line in its physical configuration: the pump was entirely contained within the pericardial space, with no pump housing in the abdominal wall. The inflow cannula and the centrifugal pump were integrated into a single compact unit implanted in the pericardial space, connected to an outflow graft anastomosed to the ascending aorta and a driveline exiting through the upper abdominal wall.

This pericardial placement was both the HVAD’s primary innovation and a key advantage over the HeartMate II (which placed the pump in the abdomen): the HVAD required no abdominal dissection, reducing some surgical complexity and making it suitable for smaller patients in whom an abdominal pump could not fit. The HVAD was FDA-approved in 2012 under PMA for bridge to transplant and in 2017 for destination therapy.

The HVAD pump used a hybrid bearing system (magnetic and hydrodynamic levitation, but not full magnetic levitation): the impeller was partially suspended by magnetic repulsion and partially by a fluid film at the pivot bearing. This partial bearing contact, while an improvement over earlier mechanical bearing designs, was not equivalent to the full magnetic levitation of the HeartMate III, and bore-related wear contributed to the pump’s performance characteristics over time.

The HVAD is now history in terms of new implants. The platform was permanently discontinued following the 2021 recall. Understanding its story matters for three reasons:

1. Approximately 4,000 patients were still living with HVADs worldwide at the time of recall, and they and their physicians need to understand the long-term management of an orphaned device.
2. The HVAD-HeartMate III comparison trials (primarily the ENDURANCE and ENDURANCE Supplement trials) generated the evidence base that informed the superiority of the HeartMate III.
3. The history of the HVAD illustrates the regulatory and clinical challenges inherent in iterative device development in a high-stakes, small-volume patient population.

The History of LVADs: From Pulsatile Displacement to Magnetic Levitation

3.1 Generation 1: Pulsatile Volume Displacement Pumps (1960s–2000s)

The concept of mechanical cardiac assistance predates the modern clinical LVAD by decades. Michael DeBakey and colleagues used the first clinical LVAD in 1963, supporting a 42-year-old woman in cardiogenic shock following open heart surgery. The device was a pneumatically driven pump that filled and emptied a flexible blood sac in synchrony with the native heart, providing pulsatile flow. It was effective for hours to days but not designed or built for chronic support.

The subsequent two decades saw incremental progress toward a device that could support a patient for weeks and eventually for long-term use. The 1980s brought the Novacor (World Heart) and the ThermoCardiosystems HeartMate I (HeartMate VE), both pulsatile displacement pumps that used a flexible pusher plate or diaphragm driven by an electric motor or pneumatic actuator. These devices were large (requiring abdominal implantation in a preperitoneal pocket), noisy (audible clicks with each pump cycle), and had limited durability (typically 1 to 2 years before mechanical failure), but they proved the concept that a patient could leave the hospital, return home, and live months on mechanical circulatory support.

The landmark REMATCH trial (Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure) established the first RCT evidence for LVAD as destination therapy 5 / Solid . The trial enrolled 129 patients ineligible for cardiac transplantation and randomized them to the HeartMate VE pulsatile pump versus target medical therapy. At 1 year, survival was 52% with LVAD versus 25% with medical therapy; at 2 years, 23% versus 8%. The HeartMate VE received FDA PMA approval for destination therapy in 2003. REMATCH demonstrated that mechanical circulatory support, despite its complexity and adverse events, provided a survival benefit over target medical therapy in patients with end-stage heart failure who could not receive a transplant.

The pulsatile pumps’ main limitations were:

• Size: too large for many female patients and patients with small body surface area
• Durability: the moving valves and diaphragm components had a mechanical lifespan of approximately 18 to 24 months; device failures were common beyond 2 years
• Infection: the large pump pocket was a significant infection risk
• Driveline failure: the percutaneous driveline was under constant mechanical stress with the pulsatile pump’s moving components

3.2 Generation 2: Continuous Axial-Flow Pumps (2000s–2010s)

The transition to continuous-flow LVADs represented the most significant change in mechanical circulatory support philosophy. Instead of filling and ejecting a blood volume in discrete cycles, an axial-flow impeller spins continuously, accelerating blood along the axis of a tube. This allowed dramatic miniaturization: the HeartMate II, the dominant second-generation device, was roughly the size of a D-cell battery.

The physiologic implications were initially a concern: the continuous flow from an axial pump produces a continuous blood pressure waveform with reduced pulsatility. Physiologists had predicted that the absence of pulsatile flow might harm end-organ perfusion. In practice, this concern was largely not borne out; most organs tolerate continuous flow well, and the improvement in cardiac output from the LVAD more than compensated for the loss of pulsatility in most patients.

The HeartMate II entered clinical trials in 2005 and received FDA PMA approval for bridge to transplant in 2008 and for destination therapy in 2010. The ADVANCE bridge-to-transplant trial and the HeartMate II destination therapy trial established its superiority over the pulsatile HeartMate I 5 / Solid : at 2 years, event-free survival (survival free of disabling stroke or device failure) was 46% with the HeartMate II versus 11% with the pulsatile device.

The remaining limitation of the HeartMate II was pump thrombosis: clot formation on or within the axial impeller assembly, occurring at rates of 8 to 10% per year. Pump thrombosis could manifest as raised LDH, hemolysis, pump power fluctuations, and, in severe cases, embolic stroke or pump failure requiring emergency replacement. This complication drove the development of the third generation.

The HVAD entered the competition during this axial-flow era as a centrifugal-flow alternative to the HeartMate II’s axial design. The centrifugal impeller produced lower shear forces and a wider flow profile, and its pericardial implant position offered anatomic advantages.

3.3 Generation 3: Centrifugal-Flow with Magnetic Levitation (2010s–present)

The third generation addressed the bearing problem. The HeartMate III (Abbott) and the HVAD (HeartWare/Medtronic) both used centrifugal flow but differed critically in their impeller suspension:

• HeartMate III: full magnetic levitation (no bearing contact), developed by Thoratec (acquired by Abbott in 2015)
• HVAD: hybrid levitation (magnetic repulsion plus hydrodynamic bearing film at a pivot point), meaning some mechanical contact persisted

The ENDURANCE trial compared the HVAD to the HeartMate II in 446 patients randomized for destination therapy 5 / Solid . The HVAD met the noninferiority criterion for the primary endpoint (survival free of disabling stroke or device failure at 2 years: 55.4% HVAD vs 59.1% HM-II, within the prespecified margin). However, the HVAD had a higher rate of stroke (29.7% vs 12.1%, p<0.0001), which drove important safety concerns and subsequent design modifications (the ENDURANCE Supplement trial with protocol modifications).

The MOMENTUM 3 trial then compared the HeartMate III to the HeartMate II and demonstrated clear superiority as described in DEVI-016, establishing the HeartMate III as the superior continuous-flow platform.

3.4 The HVAD Recall: 2021

The 2021 recall centered on two issues:

1. A software-related controller failure that could prevent the pump from restarting after being stopped. In patients dependent on the device for cardiac output, failure to restart could be fatal.
2. Higher neurological event rates compared to the HeartMate III, as evidenced by post-market data accumulation.

The FDA classified the recall as a Class I action (the most serious category, involving situations where use of or exposure to a product may cause serious adverse health consequences or death). Medtronic’s response was to halt new HVAD implants globally and ultimately to permanently discontinue the program.

For patients already implanted: the clinical recommendation at most LVAD centers was to continue HVAD support with enhanced monitoring, more frequent battery checks, and education about the controller alarm protocols. Patients with strong residual cardiac function (those receiving the device as bridge to recovery) were considered for device removal. Patients with no residual function were counseled about device exchange to the HeartMate III, a high-risk operation (requiring re-sternotomy) to be considered case-by-case based on individual risk-benefit assessment.

Clinical Implications for Current HVAD Patients

4.1 The Orphaned Device Problem

When a medical device is recalled and discontinued, the patients living with that device face a clinical reality that is unusual in medicine: they depend on a device for which no new replacement parts, no continued manufacturer support, and no access to the original development team will exist over the long term. The HeartWare HVAD controller and driveline components continue to function in most patients; the mechanical impeller has not been found to have a finite lifespan that mandates replacement at a fixed interval. But when components fail, replacement inventory from Medtronic’s existing stock is the only source, and that stock is finite.

LVAD centers with existing HVAD patient populations maintain component inventories and have established protocols for HVAD management. Patients should be followed at a center with specific HVAD expertise, not at a general cardiologist’s office without device-specific knowledge.

4.2 HVAD-to-HeartMate III Exchange

Device exchange in an already-implanted LVAD patient is technically demanding and carries significant operative mortality (estimated 10 to 20% 30-day mortality in most series, higher than primary implant due to re-sternotomy adhesions, prior sensitization, and the underlying illness burden) 3 / Early . The decision to pursue exchange must weigh:

• The patient’s current quality of life and functional status on the HVAD
• The presence of ongoing HVAD-specific complications (pump thrombosis, neurological events, restart failure history)
• The patient’s surgical risk (frailty, renal function, right ventricular function)
• The patient’s transplant candidacy (if transplant is near, waiting may be preferable to exchange)

For patients who are clinically stable on the HVAD without major complications, many experienced centers recommend continued HVAD support with surveillance rather than elective exchange, given the procedural risk.

The Evidence: Comparative Outcomes and Lessons

5.1 ENDURANCE vs. MOMENTUM 3: The Diverging Outcomes

The critical comparison: in ENDURANCE, HVAD had a 2-year stroke rate of 29.7%. In MOMENTUM 3, HeartMate III had a 2-year disabling stroke rate of 10.6%. This difference in neurological outcomes, while reflecting both device-specific and population differences, contributed substantially to the HeartMate III’s market and clinical dominance.

The mechanism of HVAD’s higher stroke rate is not fully established. Hypotheses include differences in flow dynamics at the inflow cannula, the hybrid bearing contact-related microembolization, and the higher thrombus formation rates on the HVAD’s flow path. The ENDURANCE Supplement trial modified the speed setting and anticoagulation protocol, reducing the stroke rate somewhat, but the gap with the HeartMate III was not closed.

5.2 Lessons from LVAD History

Three durable lessons emerge from the first six decades of LVAD development:

Lesson 1: Mechanical bearing contact is the limiting factor. Every generation of LVAD that involved mechanical contact between moving parts eventually encountered wear-related failure or thrombosis at those contact points. The full magnetic levitation of the HeartMate III removes this limiting factor. Future devices will almost certainly maintain full magnetic or fluid-dynamic levitation as a prerequisite.

Lesson 2: Stroke is the irreducible adverse event. Even with target anticoagulation and device design, thromboembolic stroke rates in LVAD patients remain substantially higher than in the general population. Every device generation has reduced stroke rates but not eliminated them. The HeartMate III’s reduction to 10.6% disabling stroke at 2 years is a meaningful improvement over prior generations, but it is not zero, and it remains one of the most feared complications of LVAD therapy.

Lesson 3: The speed of device iteration outpaces long-term outcomes data. The HVAD was approved for destination therapy in 2017 and recalled in 2021. The 4-year window between approval and recall illustrates the inherent limitation of PMA approval based on 2-year trial data when the expected device duration is 5 to 10 or more years. This is not a regulatory failure alone; it reflects the difficulty of conducting 5- or 10-year RCTs in a patient population with advanced heart failure, where the endpoint distribution changes as competing risks (transplant, death from non-device causes) accumulate over time.

The Patient Experience: Living Through an LVAD Era Transition

The teacher from Evanston with the HVAD implanted in 2018 is now in a different position than she expected when she left the hospital. She was told in 2018 that the HVAD was a well-established device with years of support behind it. By 2021, the device she was living with was recalled.

What she experiences is the combination of three distinct fears:

1. The acute fear of restart failure (which she understands is very rare but which the recall letter described in terms she found difficult to interpret)
2. The chronic fear of the orphaned device: what happens in 5 years when her controller needs a replacement and the company no longer manufactures them?
3. The decision about whether to undergo exchange surgery, with its known 10 to 20% operative mortality, when she is currently doing reasonably well

These fears are rational. They are also manageable, but only in the context of a trusting relationship with an LVAD team that has specific HVAD expertise and that communicates clearly about both risk and plan.

The physician’s job in this conversation is not to minimize the concern but to situate it correctly: restart failure, the specific recall indication, occurs in a rare set of circumstances (specific controller models, specific software versions) that can be addressed by controller monitoring and, for the highest-risk situations, controller exchange to a corrected version. The orphaned device problem is real but is being managed at the institutional level with inventory maintenance. The exchange surgery question requires an individualized risk-benefit discussion that takes her current functional status, HVAD complication history, transplant status, and surgical risk into account.

6.1 Sex Differences in LVAD History

Women have been systematically underrepresented in LVAD trials throughout the history of the technology. In REMATCH, women were 20% of the cohort. In MOMENTUM 3, women were 23%. This underrepresentation limits the statistical power to detect sex-specific differences in outcomes. The available data show that women who receive LVADs have higher rates of right ventricular failure, bleeding complications, and device-patient size mismatch than men, but similar or better survival when appropriately supported 4 / Promising . The lower LVAD implantation rate in women likely reflects both referral bias and physiologic differences in how women present with advanced heart failure (more preserved ejection fraction, more nonischemic etiology).

Decisions and Trade-Offs

7.1 What the HVAD History Teaches About Device Adoption Timing

For patients and physicians evaluating a new device, the HVAD history is a cautionary note about PMA approval timing: FDA PMA approval, even with 2-year RCT data, does not guarantee 5- or 10-year performance. The HeartMate III’s superiority was established against the HeartMate II in MOMENTUM 3. The HeartMate III has been in use since 2017, and its 5-year outcomes data are now emerging from registries. Those data remain favorable 4 / Promising , but the general principle remains: long-term device performance in a new technology requires long-term real-world data, not just 2-year RCT data.

7.2 Right Ventricular Function Assessment: The Universal Requirement

Regardless of LVAD generation or platform, the preoperative assessment of right ventricular function remains the most critical predictor of post-implant outcomes. This has not changed across device generations. The metrics that predict RV failure (RAP-to-PCWP ratio greater than 0.63, RVSWI below 0.25 mmHg·L/m2, severe tricuspid regurgitation, markedly raised bilirubin, and creatinine) are patient-specific and hemodynamically derived, not device-specific. Right heart failure after LVAD implantation kills patients regardless of which generation LVAD they received.

7.3 Geographic Access and Institutional Expertise

The lessons of LVAD history apply most directly at the institutional level: centers with high LVAD volume have better outcomes, shorter ICU stays, lower complication rates, and more experienced coordinators than low-volume centers 5 / Solid . This volume-outcomes relationship has been recognized by CMS in its LVAD destination therapy certification requirements, which mandate minimum implant volumes for reimbursement. In Illinois, Northwestern Memorial Hospital, University of Chicago Medical Center, Rush University Medical Center, and Loyola University Medical Center are the primary LVAD centers for the state’s population, with the entire range of device technologies and post-implant management expertise.

Clinical Synthesis

The history of LVADs is ultimately a history of buying time. The pulsatile pumps of the 1980s and 1990s bought months. The HeartMate II bought 1 to 3 years. The HeartMate III is buying 3 to 5 years or more. The biological problems, the failing myocardium, the ongoing heart failure, the comorbidities, the organ damage that accrued before the device was implanted, are not solved by any of these generations. They are managed against.

The core clinical thesis is that the majority of the patients who reach INTERMACS profile 2 or 3 and require an LVAD got there through a preventable process. The question preventive cardiology asks is not “how can we make LVADs better?” (that is the engineers’ job, and they have been doing extraordinary work for 60 years). The question is: how do we find the patients who are going to need an LVAD in 15 years, when they are still in the stage where the trajectory can be redirected?

The answer is the same as it is for every advanced cardiovascular disease: early identification (ApoB, Lp(a), coronary calcium), early intervention (statin therapy, PCSK9 inhibitors, lifestyle, blood pressure control), and a ongoing relationship with a cardiologist who tracks the trajectory rather than responding only to crises.

The history of LVADs, from the first pneumatic pump in 1963 to the fully magnetically levitated HeartMate III in 2017, is one of the great achievements of biomedical engineering in the 20th and 21st centuries. The goal of preventive cardiology is to make sure that achievement remains a triumph of last resort, not a treatment of first contact.

Appendix: Extended Clinical Notes

A.1 The REMATCH Trial and the Birth of Destination Therapy

REMATCH (Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure) established the clinical rationale for LVAD therapy in patients ineligible for cardiac transplantation. Published in the New England Journal of Medicine in 2001, REMATCH enrolled 129 patients with end-stage heart failure and randomized them to HeartMate XVE (pulsatile left ventricular assist device) versus target medical management 5 / Solid .

The results were striking: 1-year survival was 52% in the LVAD group versus 25% in the medical therapy group; 2-year survival was 23% versus 8%. The LVAD group had significantly higher quality of life scores and six-minute walk distance at 1 year. However, the device failure rate was 35% at 2 years, driven by bearings failure in the pulsatile mechanical pump. The adverse event profile included a high rate of infection (28% per patient-year), stroke (17% per patient-year), and device failure requiring reoperation 5 / Solid .

REMATCH was decisive in establishing that mechanical circulatory support extended life and improved quality of life beyond what medical therapy could achieve, but it was equally clear that the pulsatile HeartMate XVE was a first-generation device with unacceptable mechanical failure rates. This verdict drove the engineering pivot toward continuous-flow rotary pump technology that produced the HeartMate II, HeartWare HVAD, and ultimately the HeartMate III. Every patient receiving a HeartMate III today is receiving a device whose existence was made possible by REMATCH’s honest reckoning with what first-generation devices could not achieve 5 / Solid .

A.2 HeartMate II: The Axial Flow Era and What Was Learned

The HeartMate II used an axial flow design: a single rotating impeller suspended on contact bearings, spinning at 8000-10000 RPM to create continuous non-pulsatile forward flow. The ADVANCE trial (2009) and the subsequent HeartMate II destination therapy trial (Slaughter MV et al., 2009) demonstrated that HeartMate II achieved a 58% survival at 2 years for destination therapy, compared to 24% for medical therapy in the REMATCH-era control arm 5 / Solid .

The clinical advance over the HeartMate XVE was substantial: the device was much smaller (could be implanted in a woman or small adult), it had no moving valve components, and the bearing wear rate was far lower. However, the axial flow design created bearing contact points that generated thrombus, and the clinical presentation of pump thrombosis became a recurring challenge. By 2013-2014, pump thrombosis rates reported from U.S. programs had risen substantially above the clinical trial rates, with some centers reporting rates of 8-10% per patient-year 5 / Solid .

The cause of the increased thrombosis rate was multifactorial: changes in anticoagulation management at expanded centers, alterations in driveline manufacturing that changed flow dynamics, and under-recognition of early pump thrombus before it became hemodynamically significant. This experience directly motivated the design change to full magnetic levitation in the HeartMate III, which eliminated bearing contact entirely and resolved the pump thrombosis problem 5 / Solid . The HeartMate II pump thrombosis crisis of 2013-2015 illustrates a recurring theme in medical device history: controlled trial populations managed by highly experienced centers do not always predict real-world device performance across the broader clinical landscape.

A.3 The HeartWare HVAD: Centrifugal Design and Its Unique Complications

The HVAD (HeartWare International, later acquired by Medtronic) was a centrifugal flow pump with a unique intrapericardial placement design. Unlike axial flow devices implanted in the abdominal wall, the HVAD sat within the pericardial space with the inflow cannula directly at the left ventricular apex and the pump body adjacent to the heart. This design required no abdominal pocket dissection, reducing surgical trauma and potentially enabling implantation in smaller patients 4 / Promising .

The ENDURANCE trial compared HVAD to HeartMate II for destination therapy, enrolling 450 patients with advanced heart failure 5 / Solid . HVAD was noninferior to HeartMate II for the 2-year survival endpoint (41.0% versus 36.4% free of disabling stroke or death). However, a higher rate of neurologic adverse events was observed in the HVAD group (29.7% versus 12.1% for stroke), a finding that raised serious concerns about the HVAD’s safety profile 5 / Solid . Subsequent analysis attributed the higher stroke rate to the centrifugal pump’s higher shear stress exposure, the wax-wane flow pattern creating regions of blood stasis near the pump inlet, and in some cases the particular geometry of the inflow cannula positioning.

The HVAD’s intrapericardial placement also created a distinctive complication: inability to achieve mediastinal decompression if the device needed emergent explanation. In a patient with HVAD who developed pump thrombosis or driveline infection requiring surgical removal, the re-entry into the pericardial space was complicated by the device geometry, increasing operative mortality compared to HVAD explanation in non-emergency settings 3 / Early .

A.4 The 2021 HVAD Recall: Regulatory Process and Clinical Management

The June 2021 Medtronic voluntary recall of the HVAD was one of the most consequential medical device actions of the decade in advanced heart failure. The recall was triggered by post-market surveillance data showing that the HVAD restart failure rate was higher than acceptable: in patients where the HVAD stopped (due to power loss, suction event, or device dysfunction) and a restart was attempted, the device failed to restart in a proportion of cases sufficient to cause patient deaths 5 / Solid .

The FDA Medical Device Reporting database had accumulated reports of HVAD restart failures associated with patient deaths beginning in 2017, but the volume of reports reached a threshold requiring market withdrawal action by 2021. Medtronic’s decision to stop sales and manufacturing was also influenced by the MOMENTUM 3 data showing HeartMate III’s superiority, which meant there was a superior alternative available for new implants 5 / Solid .

The clinical management challenge post-recall was immense: approximately 4,000-5,000 patients globally were living with implanted HVADs that could not be explanted safely except in the context of transplantation or death. For these patients, the recall did not mean device removal; it meant intensified monitoring, mandatory patient and caregiver training on emergency HVAD management, and a clear action plan for device malfunction. At Carle Foundation Hospital, all HVAD patients in the program received an emergency management briefing within 2 weeks of the recall, including hands-on training in the emergency restart protocol (power cycling procedure) and explicit documentation in the electronic health record of HVAD status for any emergency department or ICU team that might encounter the patient. Rush University Medical Center in Chicago established a dedicated HVAD hotline for its 80+ implanted patients 3 / Early .

A.5 The CentriMag: Surgical Short-Term MCS and Its Role in the MCS Ecosystem

The CentriMag Ventricular Assist System (Abbott) occupies a distinct and important position in the MCS ecosystem that differs from all percutaneous devices discussed in this series. CentriMag is an extracorporeal centrifugal pump driven by a magnetically levitated impeller, connected to the heart via surgical cannulas implanted in the operating room under cardiopulmonary bypass. It is capable of providing left, right, or biventricular support, and can generate flows of up to 10 L/min 4 / Promising .

CentriMag is used in three distinct contexts: (1) as a bridge to LVAD implantation in patients with cardiogenic shock who are too unstable for immediate HeartMate III implantation, (2) as biventricular support after HeartMate III implantation when the right ventricle fails despite medical management, and (3) as a bridge to transplantation or recovery in patients with acute myocarditis or post-cardiotomy shock 4 / Promising . Its surgical nature means it is not an emergency room or cardiac catheterization laboratory device; it requires operating room infrastructure and surgical team availability.

At Carle Foundation Hospital, CentriMag availability is maintained on a 24-hour basis through the cardiothoracic surgery team in collaboration with the advanced heart failure program. The decision to escalate from Impella or ECMO to CentriMag surgical MCS is made jointly by the intensivist, cardiac surgeon, and heart failure cardiologist, using criteria that include: failure to achieve adequate end-organ perfusion on maximal percutaneous support, anticipated need for more than 7 days of MCS, and anatomy prohibiting percutaneous device placement. The transition from percutaneous to surgical MCS in the setting of acute heart failure is one of the highest-acuity decisions in cardiovascular medicine, and it highlights why MCS device knowledge is a prerequisite for any cardiologist treating advanced heart failure patients.

A.6 Myocardial Recovery on LVAD Support

A minority of LVAD-supported patients achieve sufficient myocardial recovery to allow device explantation without transplantation. This phenomenon, once considered rare, is increasingly recognized and systematically studied. The HARPS (Harefield Assistance in Recovering the Pumping of the Failing Heart) protocol, developed at Harefield Hospital in the United Kingdom, used high-dose clenbuterol (a beta-2 agonist that promotes cardiomyocyte hypertrophy) combined with LVAD unloading and demonstrated device explantation in approximately 70% of patients with non-ischemic dilated cardiomyopathy 3 / Early . These results have not been replicated at comparable rates in U.S. centers, and the true explantation rate in unselected LVAD populations is closer to 1-5% 3 / Early .

Predictors of myocardial recovery include: younger age, shorter duration of heart failure prior to LVAD implantation, non-ischemic etiology, absence of significant fibrosis on endomyocardial biopsy, and early return of aortic valve opening within weeks of LVAD support. The physiologic mechanism involves cardiac unloading reducing wall stress, allowing cardiomyocyte hypertrophy to normalize and calcium handling to improve 4 / Promising .

At Carle Foundation Hospital, LVAD patients under age 50 with non-ischemic cardiomyopathy are enrolled in a standardized myocardial recovery assessment protocol at 6 months, 12 months, and 24 months post-implant. The protocol includes echocardiography, cardiopulmonary exercise testing, and right heart catheterization with LVAD speed reduction to assess native cardiac function. Patients meeting pre-specified recovery criteria (EF above 45% on low-speed study, PCWP below 15 mmHg, peak VO2 above 14 mL/kg/min) are considered for LVAD explantation with close monitoring in the subsequent 24 months.

A.7 Patient Life on LVAD Support: Functional Status and Quality of Life Metrics

Quality of life data from the MOMENTUM 3 trial and subsequent registries demonstrate that HeartMate III support produces clinically meaningful improvements in functional status and patient-reported outcomes. In MOMENTUM 3, the Kansas City Cardiomyopathy Questionnaire (KCCQ) total symptom score improved from a median of 33 points at baseline to 64 points at 6 months in the HeartMate III group, a change that exceeds the minimally clinically important difference of 5 points by more than tenfold 5 / Solid . The six-minute walk test distance increased from a median of 184 meters at baseline to 300 meters at 6 months, crossing the threshold associated with meaningful community ambulation.

These functional improvements come with real restrictions. LVAD patients cannot: swim or submerge the driveline exit site, participate in contact sports, use MRI scanners unless their specific device has conditional MRI labeling, or travel to areas where reliable electrical power is unavailable (the system controller requires charging every 12-14 hours) 4 / Promising . Battery failure during device controller malfunction is a life-threatening event; patients carry spare controller and battery equipment at all times and are trained in emergency controller exchange. At Carle Foundation Hospital, all HeartMate III patients are provided with a laminated emergency card listing the device type, serial number, and 24-hour LVAD support line, and are instructed to present this card to any emergency room physician before any acute care encounter to enable correct interpretation of examination findings (the absence of a palpable pulse or standard blood pressure reading, since continuous-flow devices produce mean arterial pressure without pulsatility detectable by standard sphygmomanometry) 5 / Solid .

The myocardial recovery program at Carle Foundation Hospital feeds directly into structured remote monitoring tier for LVAD patients post-explant. Patients who achieve successful LVAD explantation have demonstrated that their myocardium responded to unloading; they have not demonstrated that the underlying cardiomyopathy is cured. Remote ECG monitoring via Zio patch at 3-month intervals, serial echocardiography every 6 months, and neurohormonal biomarker tracking (BNP or NT-proBNP) are maintained for a minimum of 3 years post-explant to detect early recurrence 4 / Promising . Patients who show rising BNP without clinical symptoms are evaluated for early re-listing rather than waiting for decompensation. The goal of the LVAD recovery program is to make successful LVAD explantation the beginning of a long-term secondary prevention commitment rather than the endpoint of a successful device story. The LVAD implanted in the 45-year-old with non-ischemic cardiomyopathy may save their life; the subsequent 30 years of cardiovascular risk management determines whether they reach 75 or 60. That long-term commitment is the Stop Dying Early mandate, expressed through the specific biology of mechanical circulatory support and myocardial recovery.

The history of LVAD therapy from REMATCH through HeartMate II pump thrombosis through the HVAD recall to the HeartMate III MOMENTUM 3 success is a compressed 25-year demonstration of how medical device development works at its best and worst: at its best, iterating aggressively on engineering failures to produce a device that is meaningfully safer; at its worst, allowing market expansion to outpace the institutional infrastructure needed to deploy devices safely. The lesson for the next generation of advanced heart failure cardiologists at Carle Foundation Hospital and beyond is that no trial result is permanent. The device that is superior today will be replaced by a device that is superior tomorrow. The clinical skill that remains constant is the ability to read the evidence, apply it appropriately to the patient in front of you, and communicate both the benefits and the uncertainty honestly. That is the Mogire standard, and it applies whether the device is a 1952-era pacing wire or a 2025 fully levitated rotary pump.

The Signal Check is fifteen questions mapping the cardiovascular risk pattern across the physiological domains most commonly missed in standard screenings. It produces a specific starting point for your next clinical conversation.